TY  - CONF

T1  - Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

JO  - Journal of Clinical Oncology

PY  - 2013/02/20

AU  - Nilsson S

AU  - Sartor AO

AU  - Bruland OS

AU  - Fang F

AU  - Aksnes A-K

AU  - Parker C

ED  - 

DO  - DOI: 10.1200/jco.2013.31.6_suppl.19

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 6_suppl

SP  - 19

EP  - 19

Y2  - 2025/10/10

ER  -